Statera Biopharma, Inc.: 10-Q filed 2017-05-15

Name: Statera Biopharma, Inc.: 10-Q filed 2017-05-15
Creator: Statera Biopharma, Inc.

What Statera Biopharma, Inc. reported in its quarterly report filed 2017-05-15 (fiscal Q1 2017): 26 published measures, 54 facts as tagged in accession 0001318641-17-000028.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-05-15
Fiscal period: fiscal Q1 2017
Accession: 0001318641-17-000028 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Statera Biopharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-03-31	13,881,770	USD
At 2016-12-31	15,955,870	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-03-31	2,635,659	USD
At 2016-12-31	3,109,089	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-03-31	5,927,254	USD
At 2016-12-31	7,523,970	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-03-31	3,820,504	USD
At 2016-12-31	6,901,816	USD
At 2016-03-31	10,594,828	USD
At 2015-12-31	5,918,424	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-1,663,694	USD	90
2016-01-01 to 2016-03-31	-667,936	USD	91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-03-31	-152,403,850	USD
At 2016-12-31	-150,740,156	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	0	USD	90
2016-01-01 to 2016-03-31	0	USD	91

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-03-31	29,597	USD
At 2016-12-31	37,376	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-1,619,448	USD	90
2016-01-01 to 2016-03-31	-2,312,306	USD	91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-03-31	13,821,433	USD
At 2016-12-31	15,887,941	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-03-31	2,635,659	USD
At 2016-12-31	3,109,089	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-03-31	379,213	USD
At 2016-12-31	336,435	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2017-03-31	516,432	USD
At 2016-12-31	352,700	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	2,194,422	USD	90
2016-01-01 to 2016-03-31	3,124,806	USD	91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	1,416,998	USD	90
2016-01-01 to 2016-03-31	1,941,240	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-03-31	10,987,166	shares
At 2016-12-31	10,987,166	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2017-03-31	-497,581	USD
At 2016-12-31	-564,559	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2017-03-31	11,246,111	USD
At 2016-12-31	12,846,781	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2017-03-31	30,740	USD
At 2016-12-31	30,553	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-03-31	1,185,329	USD
At 2016-12-31	1,823,235	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-1,700,087	USD	90
2016-01-01 to 2016-03-31	-670,742	USD	91

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-1,596,716	USD	90
2016-01-01 to 2016-03-31	-667,781	USD	91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	777,424	USD	90
2016-01-01 to 2016-03-31	1,183,566	USD	91

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	5,716	USD	90
2016-01-01 to 2016-03-31	26,617	USD	91

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	49,289	USD	90
2016-01-01 to 2016-03-31	181,765	USD	91

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-80,639	USD	90
2016-01-01 to 2016-03-31	1,641,564	USD	91

Inspect the source

Entity: Statera Biopharma, Inc. / CIK 0001318641
Captured: 2026-09-22 19:44 UTC
SEC response SHA-256: 9e499247f86d1cf9ca87ba87bfcdf37d42baa7907f4baa6e983f1992a49045f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001318641.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))